Assay Detail
Functional
CHEMBL5057382
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Reversal of resistance to paclitaxel-induced cytotoxicity in human SW-620/AD300 cells assessed as reduction in paclitaxel IC50 at 1 uM preincubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 4.23 +/- 0.50 uM)
7
Total Activities
7
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Homo sapiens |
| Cell Type | SW-620 |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Publication
Discovery of the Triazolo[1,5-<i>a</i>]Pyrimidine-Based Derivative WS-898 as a Highly Efficacious and Orally Bioavailable ABCB1 Inhibitor Capable of Overcoming Multidrug Resistance.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 7 | 7.00 | 7.55 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL5070340 | — | — | 1 | 7.55 |
| CHEMBL4776099 | — | — | 1 | 7.24 |
| CHEMBL4091439 | — | — | 1 | 7.12 |
| CHEMBL4781900 | — | — | 1 | 6.96 |
| CHEMBL5085203 | — | — | 1 | 6.92 |
| CHEMBL5084491 | — | — | 1 | 6.62 |
| CHEMBL5086344 | — | — | 1 | 6.58 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL5070340 | — | IC50 | = | 28.15 | nM | 7.55 |
| CHEMBL4776099 | — | IC50 | = | 58.0 | nM | 7.24 |
| CHEMBL4091439 | — | IC50 | = | 75.0 | nM | 7.12 |
| CHEMBL4781900 | — | IC50 | = | 110.0 | nM | 6.96 |
| CHEMBL5085203 | — | IC50 | = | 120.0 | nM | 6.92 |
| CHEMBL5084491 | — | IC50 | = | 240.0 | nM | 6.62 |
| CHEMBL5086344 | — | IC50 | = | 260.0 | nM | 6.58 |